Key Findings:  This study of human keratinocytes and the effects of lesser-known phytocannabinoids in-vitro finds that they are able to modulate the endocannabinoid system (ECS) differently, as well as alter the content of endocannabinoid compounds. All four compounds, CBC, CBG, THCV, and CBGA altered CB1/2 binding, TRPV1 simulation, and FAAH and MAGL activity. These activities could lead to novel therapies that can better target disorders of the skin.
Type of Study:  Laboratory Study
Study Result:  Positive
Study Location(s):  Canada, Italy
Year of Pub:  2022
Cannabinoids Studied:  Cannabichromene (CBC), Cannabigerol (CBG), Cannabigerolic Acid (CBG-a), Anandamide (AEA), Fatty Acid Amide Hydrolase (FAAH), 2-Arachidonoyl Glycerol (2-AG), Monoacylglycerol Lipase (MAGL), Endocannabinoid (unspecified), Tetrahydrocannabivarin (THCV), Palmitoylethanolamide (PEA)
Phytocannabinoid Source:  Unspecified
Receptors Studied:  CB1, CB2, GPCR 55, TRPV1, PPAR - Alpha, PPAR - Beta Delta, PPAR - Gamma